Outperformance Should Continue with Backlog up 37% & Acquired Vention
- EPS is projected up 16% in FY17 to a record $5.40 and a further 16% in FY18 to $6.25, aided by the April 31st backlog up 37% to $403 million, new products, acquisition benefits and effective margin improvement initiatives.
- With Vention Medical (acquired March 2017 for $705 million), Nordson now generates around 15% of sales in higher growth & less cyclical healthcare markets.
- Parts and consumables account for 40% of sales, providing recurring revenue.
- International markets, approximately 71% of sales, are longer-term growth drivers.
- Dividends have been increased annually for 53 years, a record only 13 other publicly traded companies can meet or exceed.
Nordson engineers, manufactures and markets differentiated products and systems used for dispensing, applying and controlling of adhesives, coatings, polymers, sealants, biomaterials, and other fluids, to test and inspect for quality, and to treat and cure surfaces. The company serves a range of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. The company has three operating segments: Adhesive Dispensing Systems, Advanced Technology Systems, and Industrial Coating Systems.
Great Lakes Review is located in Cleveland, Ohio, was founded in 1981 and became a division of Wellington Shields & Co. LLC in 2011. Great Lakes Review is a research boutique focused on the fundamentally-oriented investor seeking companies that dominate their respective specialty niche regardless of industry. The objective is to make money for the long-term by gradually accumulating a diversified portfolio from a universe of no more than 30 companies. Although short-term-oriented accounts will be alerted to trading opportunities, aggressive sell recommendations are triggered only by a deterioration in long-term fundamentals, not by short-term blips or investor fancy. Coverage of those names that lose their earnings momentum or earnings predictability may be dropped and replaced with more vital candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.